The phase 3 clinical trial is a prospective, double-blind, randomized multicenter study in the United States. The trial includes placebo and midazolam controls.
Patient recruitment for the study is expected to reach completion in 2016.
More articles on gastroenterology:
Consumerism is taking healthcare by storm: How is GI affected?
3 GI physicians making headlines – June 5, 2015
EndoChoice IPO update: Common stock price set at $15 per share
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
